AZN · story · 14 November
AstraZeneca · 7 headlines from 7 outlets, on 14 November 2026.
The FDA approved Imfinzi with Padcev in muscle-invasive bladder cancer patients.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
AstraZeneca is the largest at 10.0, ahead of MarketScreener (10.0). Fierce Pharma is the smallest at 9.2.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| AstraZeneca | 10.0 |
| MarketScreener | 10.0 |
| FirstWord Pharma | 10.0 |
| Securities.io | 10.0 |
| MLQ.ai | 10.0 |
| Yahoo Finance | 10.0 |
| Fierce Pharma | 9.2 |
| Outlet | Headlines | Average tone |
|---|---|---|
| AstraZeneca | 1 | +10.0 |
| MarketScreener | 1 | +10.0 |
| FirstWord Pharma | 1 | +10.0 |
| Securities.io | 1 | +10.0 |
| MLQ.ai | 1 | +10.0 |
| Yahoo Finance | 1 | +10.0 |
| Fierce Pharma | 1 | +9.2 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +10.0 | Company's own notice of new US approval. |
| +10.0 | US regulator approved bladder cancer treatment. |
| +10.0 | Regulatory clearance of new bladder cancer combination expands product use. |
| +10.0 | Regimen gains US approval in bladder cancer. |
| +10.0 | Approval for patients unable to take cisplatin widens use. |
| +10.0 | Company announcement of US approval for new Imfinzi regimen. |
| +9.2 | Label expansion strengthens competition against Merck's rival drug. |
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.